A Panax plant extract and a pharmaceutical composition and the use thereof. The mass ratio of Rk1 and Rg5 in the Panax plant extract is 1:1.0-1.5, and the content of Rg3, Rg5 and Rk1 in the extract is relatively high. The extract can be used to prepare a drug for treating chronic heart failure, coronary stable angina, arrhythmia, diabetes and complications thereof, Meniere's disease, hyperlipemia, fatty liver, Alzheimer's disease, dymenorrhea, metabolic syndrome, gout, tumours or vascular leak syndrome.

In an example implementation, a method of producing an erosion-controlled release device includes accessing erosion-controlled release input data, and translating the input data into an erosion-controlled release print file. The method includes executing the erosion-controlled release print file to control a 3D printing system to produce an erosion-controlled release device that comprises an active ingredient release profile based on the erosion-controlled release input data.

The present invention relates to pharmaceutical antiretroviral compositions comprising a combination of antiretroviral agents (darunavir, dolutegravir and ritonavir), the manufacturing process thereof and use of the said compositions for the prevention, treatment or prophylaxis of HIV infection.

The present invention relates to a composite preparation in a core tablet form, composed of an inner core containing rabeprazole as an effective ingredient; an outer layer portion including the bilayer structure of a sustained release layer and an immediate release layer and containing mosapride as an effective ingredient. The core tablet composite preparation according to the present invention is characterized by exerting sufficient pharmacological activity of rabeprazole and mosapride even upon administration of one tablet once a day.

The tablet of the present invention is a tablet 1 having a cup portion 12 formed at least above or below a side portion 11, wherein the outer surface of the cup portion 12 includes first, second and third curved surfaces 12a, 12b and 12c having different curvatures R.sub.1, R.sub.2 and R.sub.3, the first curved surface 12a is at least continuous with the second curved surface 12b, the second curved surface 12b is continuous with the first curved surface 12a and the third curved surface 12c, and the third curved surface 12c is at least continuous with the second curved surface 12b.

The present disclosure provides compounds for the inhibition of soluble epoxide hydrolase and associate disease conditions, as well as a method of treating or preventing disorders in a subject by inhibition of soluble epoxide hydrolase.

Described herein are cannabinoid formulations in combination with lavender and/or a lavender extract for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof and manufacturing oral formulations as described herein.

Acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, and acid addition salt of apomorphine isobutyrate salts are disclosed. Also disclosed are pharmaceutical compositions (e.g., unit dosage forms, e.g., films) containing acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate. Further disclosed are methods of use of acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate.

There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.

The present disclosure, in some aspects, is directed to methods of designing an oral drug dosage form formulated and configured to have a desired pharmacokinetic profile. In other aspects, the present disclosure is directed to oral drug dosage forms having a desired pharmacokinetic profile, and methods of making, such as three-dimensional printing, such oral drug dosage forms.